Moreover, they reported that activation of GPER signaling inhibits melanoma and improves response to immune checkpoint blockade, which extends the comprehensive mechanisms of estrogen signal action on the etiology and carcinogenesis in melanoma, and may provide the “proof of concept” for the new therapeutic strategy for melanoma. The gene discussed is GPER1; the disease is melanoma.